Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- 2,746 Welfare Recipients Receive Psychotropics from Multiple Med Institutions
August 16, 2010
- Daiichi Sankyo: Olmetec Drives Business
August 16, 2010
- Zeria: Overseas Sales Ratio Up to 13.2% with Addition of Tillotts
August 16, 2010
- AnGes MG Obtains Patent for HFG Gene Therapy for PD in the US
August 16, 2010
- JGA Fails to Achieve No-Shortage Goal in FY2009
August 16, 2010
- Astellas: Patent Expiration Hits Business
August 16, 2010
- ASKA: Seltouch Boosts Sales
August 16, 2010
- Market for Insomnia Treatments to Expand to US$1 Bil. by 2019 in Japan: Datamonitor
August 16, 2010
- Taiyo Yakuhin Posts Measures to Improve Manufacturing Practice on Its Website
August 16, 2010
- Eisai: Sales Up 5% Driven by Good Sales of Aricept
August 16, 2010
- Seikagaku: Sales Remain Virtually Unchanged
August 16, 2010
- Sales of Ethical Drugs Up 2.3% in June: Crecon Report
August 16, 2010
- ARQ 197 to Enter PIII for NSCLC: Daiichi Sankyo, ArQule
August 16, 2010
- MTPC: Sales, Profits Up despite Biz Suspension
August 16, 2010
- JCR Pharmaceuticals: Upfront Payment from GSK Boosts Sales
August 16, 2010
- Market for Antidepressants in Japan Part II (1)
August 16, 2010
- SSP to Place Top Priority on Profit Ratio: President Shiono
August 16, 2010
- DSP: Former Sepracor Boosts Sales by 54.1%
August 16, 2010
- Wakamoto: Net Loss Increases to ¥132 Mil.
August 16, 2010
- Market for Antidepressants in Japan Part II (2)
August 16, 2010
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…